Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept in Treatment Resistant Nephrotic Syndrome (FSGS/MCD)
NCT02592798Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2016
- Primary completion
- Jan 2020
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of abatacept in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), sponsored by Bristol Myers Squibb. Started Mar 2016; status: completed.
02
Drugs
abatacept
03
Conditions
focal segmental glomerulosclerosis (FSGS)minimal change disease (MCD)
Beyond the preview
Go deeper on NCT02592798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02592798.